AstraZeneca's Imfinzi Combo Shows Survival Benefit In Pivotal Bladder Cancer Study - AstraZeneca (NYSE:AZ

AstraZeneca's Imfinzi Combo Shows Survival Benefit In Pivotal Bladder Cancer Study - AstraZeneca (NYSE:AZ

AstraZeneca PLC (NASDAQ:AZN) on Thursday said interim results from the Phase 3 VOLGA trial showed that perioperative treatment with Imfinzi (durvalumab) and neoadjuvant enfortumab vedotin significantly improved event-free survival and overall survival in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based chemotherapy. The study compared the regimen against standard treatment involving radical cystect…

AZ cues up broader use of Imfinzi in bladder cancer

The results of the VOLGA trial have buoyed AstraZeneca's ambitious growth targets for PD-L1 inhibitor Imfinzi in bladder cancer.

Perioperative Durvalumab Plus Enfortumab Vedotin Improves Survival in MIBC

Results from the phase 3 VOLGA trial demonstrate that perioperative durvalumab plus neoadjuvant enfortumab vedotin significantly improved EFS and OS in MIBC.

AstraZeneca Reports Strong Survival Benefits in Phase III VOLGA Trial for Muscle-Invasive Bladder Cancer

Open the article to view the coverage from EuropaWire.eu

AstraZeneca follows Merck with Phase 3 win in bladder cancer

A combination of AstraZeneca's Imfinzi with Pfizer and Astellas’ Padcev kept more bladder cancer patients alive than standard of care, the company said Thursday. AstraZeneca said it would seek approval for the combination, but it ...